CEO of ArQule Inc. (ARQL, Financial) Paolo Pucci buys 2,500 shares of ARQL on 05/13/2009 at an average price of $3.85 a share.
ArQule Inc. is a biotechnology company engaged in the research and development of next-generation small-molecule cancer therapeutics. The Company's targeted broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met which plays multiple roles in cancer cell growth survival invasion angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program based on the E2F-1 pathway is partnered with Roche. ArQule Inc. has a market cap of $172.5 million; its shares were traded at around $3.87 with and P/S ratio of 12.2.
ARQL is in the portfolios of Jean-Marie Eveillard of Arnhold & S. Bleichroeder Advisers, LLC, Jean-Marie Eveillard of Arnhold & S. Bleichroeder Advisers, LLC.
Recent Trades of ArQule Inc. by CEO:
Recent Trades of ArQule Inc. by Directors and Officers:
ArQule Inc. is a biotechnology company engaged in the research and development of next-generation small-molecule cancer therapeutics. The Company's targeted broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met which plays multiple roles in cancer cell growth survival invasion angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program based on the E2F-1 pathway is partnered with Roche. ArQule Inc. has a market cap of $172.5 million; its shares were traded at around $3.87 with and P/S ratio of 12.2.
ARQL is in the portfolios of Jean-Marie Eveillard of Arnhold & S. Bleichroeder Advisers, LLC, Jean-Marie Eveillard of Arnhold & S. Bleichroeder Advisers, LLC.
Recent Trades of ArQule Inc. by CEO:
- Buy: CEO Paolo Pucci bought 2,500 shares of ARQL stock on 05/13/2009 at the average price of $3.85; the price of the stock has increased by 0.52% since.
Recent Trades of ArQule Inc. by Directors and Officers:
- Buy: Director Timothy C Barabe bought 133 shares of ARQL stock on 04/29/2009 at the average price of $4.5; the price of the stock has decreased by 14% since.
- Buy: Director Michael D Loberg bought 105 shares of ARQL stock on 04/09/2009 at the average price of $4.75; the price of the stock has decreased by 18.53% since.
- Buy: Director Michael D Loberg bought 281 more shares of ARQL stock on 03/12/2009 at the average price of $3.55; the price of the stock has increased by 9.01% since.
- Buy: Director Timothy C Barabe bought 338 shares of ARQL stock on 03/12/2009 at the average price of $3.55; the price of the stock has increased by 9.01% since.
- Buy: Director Timothy C Barabe bought 206 more shares of ARQL stock on 03/04/2009 at the average price of $2.9; the price of the stock has increased by 33.45% since.
